Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluating the Safety and Efficacy of Radioactive Iodine (RAI) Treatment of Metastatic and Advanced Differentiated Thyroid Cancers by Pretreatment With Apatinib for the Neoadjuvant Regimen

NCT04180007 is registered in ClinicalTrials.gov with Nanjing First Hospital, Nanjing Medical University as lead sponsor.

NCT NCT04180007
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04180007 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluating the Safety and Efficacy of Radioactive Iodine (RAI) Treatment of Metastatic and Advanced Differentiated Thyroid Cancers by Pretreatment With Apatinib for the Neoadjuvant Regimen
Lead sponsor
Nanjing First Hospital, Nanjing Medical University
Phase
Phase 2
Overall status
Unknown status
Start date
April 10, 2019
Completion date
May 30, 2020
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

apatinib, metastasis, thyroid